1	Title: Association of Increased Fluvoxamine Use with Reports of Benefit for COVID
2	
3	Authors: Kojima N ¹ , Dima M Qato ²⁻³ and Klausner JD ⁴
4	
5	¹ Department of Medicine, University of California Los Angeles, Los Angeles, 90095
6	² Program on Medicines and Public Health, Department of Clinical Pharmacy, University
7	of Southern California, School of Pharmacy, Los Angeles, California
8	³ Schaeffer Center for Health Policy and Economics, University of Southern California,
9	Los Angeles, California
10	⁴ Department of Population and Public Health Sciences, University of Southern
11	California, Keck School of Medicine, Los Angeles, 90033
12	
13	Keywords: COVID-19; SARS-CoV-2; Vaccination; Prior infection
14	
15	
16	
17	
18	
19	
20	Corresponding Author Contact Information:
21	Department of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA
22	90095. Email: nkojima@ucla.edu
23	

Introduction: Several recent studies have found that fluvoxamine decreases the risk of serious disease progression among people with early SARS-CoV-2 infection. In this study, we examined changes in the total number of fluvoxamine tablets dispensed across retail pharmacies in the U.S.

Methods: We hypothesized that fluvoxamine prescriptions would increase substantially since March 2021 as an option for the early treatment of SARS-CoV-2 infection. We used the IQVIA National Prescription Audit (NPA) Weekly nationally projected data for prescriptions dispensed from retail pharmacies for fluvoxamine from 27 December 2019 to 31 December 2021. We performed an interrupted-time series analyses on frequency of dispensing fluvoxamine tablets.

Results: The weekly rate of dispensed tablets of fluvoxamine increased throughout the study period. The weekly number of dispensed tablets of fluvoxamine increased (11.1%) from a baseline of 1,586,154 (95% confidence interval [CI]: 1,563,960 – 1,608,348) to 1,762,381 (95% CI: 1,735,682 – 1,789,080) by December 2021.

Conclusion: Our findings are consistent with a modest increase in the use of

fluvoxamine for the treatment of COVID-19 associated with the discovery and media dissemination of the potential clinical benefit of fluvoxamine use.

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

Main Text Several recent studies have found that fluvoxamine decreases the risk of serious disease progression among people with early SARS-CoV-2 infection. 1-3 In March 2021 a widely watched news program aired a report describing the potential benefit of fluvoxamine for COVID-19.4 While several medications were developed to treat COVID-19, repurposing existing medications like fluvoxamine offer benefits, including widespread availability, known safely profiles, and low cost, that newly approved medications lack.⁵ In this study, we examined changes in the total number of fluvoxamine tablets dispensed across retail pharmacies in the U.S. We hypothesized that fluvoxamine prescriptions would increase substantially since March 2021 as an option for the early treatment of SARS-CoV-2 infection. We used the IQVIA National Prescription Audit (NPA) Weekly nationally projected data for prescriptions dispensed from retail pharmacies for fluvoxamine from 27 December 2019 to 31 December 2021. The NPA aggregates prescription data from pharmacies across the US representing approximately 92% of all retail prescription activity. We performed an interrupted-time series analyses on frequency of dispensing fluvoxamine tablets. The potential clinical benefit of fluvoxamine for COVID-19 was widely disseminated on 7 March 2021, therefore we compared periods from 27 December 2019 to 3 March 2021 and from 12 March to 31 December 2021. Adjustment for firstorder autocorrelation was made though autoregressive integrated moving average models. The weekly number of dispensed tablets of fluvoxamine were compared

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

between periods. Analyses were performed on StataSE (StataCorp, College Station, TX). The weekly rate of dispensed tablets of fluvoxamine increased throughout the study period. The weekly number of dispensed tablets of fluvoxamine increased (11.1%) from a baseline of 1,586,154 (95% confidence interval [CI]: 1,563,960 - 1,608,348) to 1,762,381 (95% CI: 1,735,682 – 1,789,080) by December 2021 (Figure). Our findings are consistent with a modest increase in the use of fluvoxamine for the treatment of COVID-19 associated with the discovery and media dissemination of the potential clinical benefit of fluvoxamine use. Other events, however, may have contributed to this temporal trend. For instance, there may have also been increased fluvoxamine prescription for the treatment of depression, which is also associated with COVID-19. However, the increased use of fluvoxamine was non-linear and appeared to rapidly increase after increased awareness of its potential COVID-19 treatment benefit. Nevertheless, as an ecological study, our results are preliminary and should be confirmed with additional studies. **Declarations** Declaration of competing interests None **Funding**

Supported in part by a gift to the Keck School of Medicine of the University of Southern California by the W.M. Keck Foundation.

Acknowledgements

This study was supported, in part, through the IQVIA Institute Human Data Science Research Collaborative. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA or any of its affiliated or subsidiary entities

References

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112


113

114

115

1. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA 2020;324(22):2292-2300. DOI: 10.1001/jama.2020.22760. 2. Seftel D, Boulware DR. Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19. Open Forum Infect Dis 2021;8(2):ofab050. DOI: 10.1093/ofid/ofab050. 3. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health 2022;10(1):e42-e51. DOI: 10.1016/S2214-109X(21)00448-4. 4. Alfonsi S. Finding a possible early treatment for COVID-19 in a 40-year-old antidepressant. 60 Minutes. CBS, 2021. (https://www.cbsnews.com/news/fluvoxamine-antidepressant-drug-covidtreatment-60-minutes-2021-03-07/). 5. Facente SN, Reiersen AM, Lenze EJ, Boulware DR, Klausner JD. Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence. Drugs 2021;81(18):2081-2089. DOI: 10.1007/s40265-021-01636-5.

Figure. Trends in the total number of dispensed tablets of fluvoxamine in retail, mail, and long-term care pharmacies in the
U.S., 27 December 2019 to 31 December 2021



*ARIMA regression of 3,234.2 (95% CI: 1,936.8 – 4,531.6; p<0.001).